Spray Dried ID93+GLA-SE
Candidate Overview
AAHI’s tuberculosis vaccine candidate includes a recombinant fusion subunit protein antigen, ID93, formulated with GLA-SE, a squalene emulsion containing the synthetic Toll-like receptor 4 agonist glucopyranosyl lipid A (GLA). The vaccine candidate was developed on AAHI’s formulation (adjuvant and delivery vehicle) vaccine platform.
Sponsor / Lead Developer: Access to Advanced Health Institute (AAHI)
Development partner(s): National Institute of Health/National Institute of Allergy and Infectious Diseases (NIAID)
Primary Indication: Prevention of TB disease
Other Indication(s): Immunotherapy/Improving TB Cure Rates, Immunotherapy/Shortening TB treatment, Prevention of Mtb infection or sustained infection, and Prevention of TB recurrence
Target Population(s): Adolescents, Adults, Elderly, and To be determined
Target Route of Administration: Aerosol
Primary endpoint: Prevention of TB disease
Immune tissue localization: Lung
Immunological responses: B-cell/Antibody and T-cell
Preclinical Animal Models: Mouse
Additional Immunologic Response Information
HYPOTHESIZED | DEMONSTRATED |
|
| Immune Response | B-cell/Antibody T-cell |
|
| Characteristics of B-cell response | Mucosal IgA | |
| T-cell phenotype | CD4 | |
| T-cell functional profile | IFN-γ TNF-α IL-17 |
|
| Preferential immune tissue localization | Lung Spleen |
|
| Trained immunity | No |
Related Publications
- Development and testing of a spray-dried tuberculosis vaccine candidate in a mouse model. (Front. Pharmacol., 2022)
- Development of a formulation platform for a spray-dried, inhalable tuberculosis vaccine candidate. (Int J. Pharm, 2021).